What is uterine artery embolization, including its indications, contraindications, procedural technique, post‑procedure care, benefits, and potential complications?

Uterine Artery Embolization Overview

Uterine artery embolization (UAE) is a minimally invasive interventional radiology procedure that occludes uterine arteries with embolic particles to induce ischemic necrosis and involution of fibroids, effectively treating bulk symptoms and heavy menstrual bleeding with comparable outcomes to myomectomy but with lower blood transfusion risk, shorter hospital stays, and reduced new fibroid formation. 1

Procedural Technique

UAE utilizes either a transfemoral or transradial arterial approach to advance a catheter into the uterine arteries under fluoroscopic guidance 1. The interventional radiologist introduces embolic materials—typically polyvinyl alcohol microspheres, gelatin particles, or coils—through the catheter to achieve arterial occlusion 1, 2. The endpoint is complete vascular exclusion with contrast stasis on final angiography, which defines technical success 3.

The procedure achieves >50% average reduction in fibroid size at 5 years with persistent decreases in pain and heavy menstrual bleeding 1.

Primary Indications

Symptomatic uterine fibroids causing:

• Heavy menstrual bleeding (menorrhagia)
• Bulk symptoms: pelvic pressure, pain, fullness, bladder or bowel dysfunction
• Anemia secondary to bleeding 1, 4

Additional gynecologic/obstetric indications include:

• Postpartum hemorrhage
• Hemorrhage during pregnancy termination
• Prophylaxis before surgical removal of retained products of conception
• Abnormal placental implantation
• Adenomyosis
• Arteriovenous malformations
• Bleeding from gynecologic malignancies 5, 3

Contraindications

Absolute contraindications:

• Active pelvic infection (risk of sepsis)
• Pregnancy (when treating fibroids electively)
• Desire for future fertility remains controversial but is increasingly accepted with proper counseling 1, 6

Relative contraindications:

• Pedunculated subserosal fibroids (risk of detachment)
• Intracavitary/submucosal fibroids (guidelines diverge; may cause vaginal expulsion) 1, 6
• Small fibroids (guidelines vary on appropriateness) 6

Post-Procedure Care and Expected Course

Immediate post-procedure (first 24-48 hours):

• Pelvic pain is universal and requires intravenous NSAIDs and narcotic analgesia 4, 7
• Monitor for post-embolization syndrome: flu-like symptoms with pain, nausea, fever, and leukocytosis 1
• Most patients require 1 week of rest before returning to activities 2

Hospital stay: Significantly shorter than surgical alternatives 1

Recovery: Faster than myomectomy or hysterectomy, with less postprocedural pain than surgical approaches 1

Benefits and Efficacy

Compared to myomectomy:

• Equally effective at reducing heavy menstrual bleeding at 4 years 1
• Lower blood transfusion risk
• Shorter hospital stays
• Significantly lower rates of new fibroid formation 1
• Similar quality of life scores and reintervention rates at 4 years 1

Compared to MR-guided focused ultrasound (MRgFUS):

• Lower reintervention rate (13% vs 30% at 2 years) 1
• Better symptom control
• Greater improvement in quality of life scores at all time points 1
• Shorter procedure time (2.3 hours vs 6.75 hours) 1

Success rates: 80-90% of patients experience relief of myoma-related symptoms 7

Potential Complications

Common side effects:

• Post-embolization syndrome (pain, nausea, fever, leukocytosis) 1
• Vaginal expulsion of submucosal fibroids 1

Rare but serious complications:

• Endometritis
• Pyometra
• Uterine necrosis requiring hysterectomy 4
• Infection leading to hysterectomy (reported in early series) 2
• Amenorrhea (some patients) 2

Major adverse event rate: Extremely low at 0.2% in recent prospective trials, compared to 12.6% for surgical approaches 1

Long-Term Outcomes and Reintervention

Reintervention rates:

• 13% at 2 years 1
• 28% secondary hysterectomy rate at 5 years
• 35% secondary hysterectomy rate at 10 years (EMMY trial data, which prohibited repeat embolization) 1

These rates are not significantly different from myomectomy at 4-year follow-up 1.

Fertility Considerations

Current evidence supports UAE for patients desiring future fertility with proper counseling 6:

• Recent prospective studies show high live birth rates (10/12 pregnancies) with low miscarriage rates (1/12) 1
• FEMME trial: 60% live birth rate (9/15 pregnancies), 33% miscarriage rate 1
• Retrospective cohort: 73% live birth rate (109/148), 17.5% miscarriage rate 1
• No significant difference in ovarian reserve biomarkers between UAE and myomectomy 1

Critical caveat: Patients must be counseled that pregnancy remains possible after UAE regardless of fertility intentions 1.

Clinical Decision-Making Algorithm

For patients with symptomatic fibroids:

1. Desires definitive treatment, no future fertility: Hysterectomy remains gold standard
2. Desires uterine preservation, no future fertility: UAE is preferred over MRgFUS (lower reintervention, better symptom control) 1
3. Desires future fertility: UAE is acceptable with counseling about pregnancy outcomes; myomectomy remains traditional surgical option 1, 6
4. Concurrent adenomyosis: UAE can treat both conditions simultaneously 1

Essential team: Experienced interventional radiologist and gynecologist collaboration is critical 6